Loading...
Header Logo
Keywords
Last Name
Institution

Priyabrata Mukherjee

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentStephenson Cancer Center
Address975 NE 10th St
Oklahoma City OK 73104-5419
Phone405/271-1133
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA136494     (MUKHERJEE, PRIYABRATA)Dec 1, 2008 - Nov 30, 2020
    NIH/NCI
    Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle
    Role: Principal Investigator

    R01CA135011     (MUKHERJEE, PRIYABRATA)May 1, 2009 - Feb 28, 2014
    NIH/NCI
    Development of a gold nanoparticles based targeted delivery system
    Role: Principal Investigator

    R01HL120585     (MUKHERJEE, PRIYABRATA)Aug 15, 2013 - Jun 30, 2018
    NIH/NHLBI
    Cystathionine beta synthase (CBS) and angiogenesis
    Role: Principal Investigator

    R01CA213278     (MUKHERJEE, PRIYABRATA)Dec 22, 2016 - Nov 30, 2021
    NIH/NCI
    Reprogramming Tumor Microenvironment by Nanoparticle
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 May 22; 8:14634. PMID: 28530221.
      View in: PubMed
    2. Banerjee Mustafi S, Chakraborty PK, Dwivedi SK, Ding K, Moxley KM, Mukherjee P, Bhattacharya R. BMI1, a new target of CK2a. Mol Cancer. 2017 Mar 07; 16(1):56. PMID: 28270146.
      View in: PubMed
    3. Ha JH, Yan M, Gomathinayagam R, Jayaraman M, Husain S, Liu J, Mukherjee P, Reddy EP, Song YS, Dhanasekaran DN. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 08; 7(45):72845-72859. PMID: 27655714.
      View in: PubMed
    4. Saha S, Xiong X, Chakraborty PK, Shameer K, Arvizo RR, Kudgus RA, Dwivedi SK, Hossen MN, Gillies EM, Robertson JD, Dudley JT, Urrutia RA, Postier RG, Bhattacharya R, Mukherjee P. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano. 2016 Dec 27; 10(12):10636-10651. PMID: 27758098.
      View in: PubMed
    5. Banerjee Mustafi S, Aznar N, Dwivedi SK, Chakraborty PK, Basak R, Mukherjee P, Ghosh P, Bhattacharya R. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 Dec; 30(12):4042-4055. PMID: 27613804.
      View in: PubMed
    6. Banerjee Mustafi S, Chakraborty PK, Naz S, Dwivedi SK, Street M, Basak R, Yang D, Ding K, Mukherjee P, Bhattacharya R. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93. PMID: 27295567; PMCID: PMC4958591 [Available on 08/01/17].
    7. Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104. PMID: 26918603; PMCID: PMC4924772.
    8. Dey A, Mustafi SB, Saha S, Kumar Dhar Dwivedi S, Mukherjee P, Bhattacharya R. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016; 12(4):659-70. PMID: 27050456; PMCID: PMC4836029 [Available on 04/06/17].
    9. Chakraborty PK, Xiong X, Mustafi SB, Saha S, Dhanasekaran D, Mandal NA, McMeekin S, Bhattacharya R, Mukherjee P. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84. PMID: 26452259; PMCID: PMC4741935.
    10. Saha S, Chakraborty PK, Xiong X, Dwivedi SK, Mustafi SB, Leigh NR, Ramchandran R, Mukherjee P, Bhattacharya R. Cystathionine ß-synthase regulates endothelial function via protein S-sulfhydration. FASEB J. 2016 Jan; 30(1):441-56. PMID: 26405298; PMCID: PMC4684530 [Available on 01/01/17].
    11. Xiong X, Arvizo RR, Saha S, Robertson DJ, McMeekin S, Bhattacharya R, Mukherjee P. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65. PMID: 25071019; PMCID: PMC4171643.
    12. Giri K, Shameer K, Zimmermann MT, Saha S, Chakraborty PK, Sharma A, Arvizo RR, Madden BJ, Mccormick DJ, Kocher JP, Bhattacharya R, Mukherjee P. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90. PMID: 24831101; PMCID: PMC4128259.
    13. Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167. PMID: 24236104; PMCID: PMC3827285.
    14. Arvizo RR, Moyano DF, Saha S, Thompson MA, Bhattacharya R, Rotello VM, Prakash YS, Mukherjee P. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8. PMID: 23615904; PMCID: PMC3682561.
    15. Arvizo RR, Saha S, Wang E, Robertson JD, Bhattacharya R, Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5. PMID: 23569259; PMCID: PMC3637766.
    16. Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8(3):e57522. PMID: 23483913; PMCID: PMC3590245.
    17. Arvizo RR, Giri K, Moyano D, Miranda OR, Madden B, McCormick DJ, Bhattacharya R, Rotello VM, Kocher JP, Mukherjee P. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650. PMID: 22442705; PMCID: PMC3307759.
    18. Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012 Apr 07; 41(7):2943-70. PMID: 22388295; PMCID: PMC3346960.
    19. Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, Mukherjee P. Switching the targeting pathways of a therapeutic antibody by nanodesign. Angew Chem Int Ed Engl. 2012 Feb 13; 51(7):1563-7. PMID: 22135077; PMCID: PMC3324088.
    20. Kudgus RA, Bhattacharya R, Mukherjee P. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem. 2011 Dec; 11(10):965-73. PMID: 21864234; PMCID: PMC4684088.
    21. Bhattacharyya S, Khan JA, Curran GL, Robertson JD, Bhattacharya R, Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater. 2011 Nov 16; 23(43):5034-8. PMID: 21971980; PMCID: PMC4684084.
    22. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011; 6(9):e24374. PMID: 21931696; PMCID: PMC3172229.
    23. Bhattacharyya S, Gonzalez M, Robertson JD, Bhattacharya R, Mukherjee P. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chem Commun (Camb). 2011 Aug 14; 47(30):8530-2. PMID: 21717027; PMCID: PMC3324332.
    24. Khan JA, Kudgus RA, Szabolcs A, Dutta S, Wang E, Cao S, Curran GL, Shah V, Curley S, Mukhopadhyay D, Robertson JD, Bhattacharya R, Mukherjee P. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347. PMID: 21738572; PMCID: PMC3124468.
    25. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918. PMID: 21445297; PMCID: PMC3061867.
    26. Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011 Oct; 7(5):580-7. PMID: 21333757; PMCID: PMC3138823.
    27. Patra CR, Jing Y, Xu YH, Bhattacharya R, Mukhopadhyay D, Glockner JF, Wang JP, Mukherjee P. A core-shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnol. 2010 Dec 01; 1(1):13-18. PMID: 21318050.
      View in: PubMed
    28. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011 Feb; 28(2):237-59. PMID: 21104301; PMCID: PMC3072278.
    29. Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14541-6. PMID: 20679244; PMCID: PMC2930461.
    30. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, Rotello VM, Prakash YS, Mukherjee P. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010 Jul 14; 10(7):2543-8. PMID: 20533851; PMCID: PMC2925219.
    31. Arvizo R, Bhattacharya R, Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv. 2010 Jun; 7(6):753-63. PMID: 20408736; PMCID: PMC2874072.
    32. Patra CR, Bhattacharya R, Mukherjee P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem. 2010 Jan 01; 20(3):547-554. PMID: 20436942.
      View in: PubMed
    33. Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010 Mar 08; 62(3):346-61. PMID: 19914317; PMCID: PMC2827658.
    34. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA, Mukherjee P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5. PMID: 19903841; PMCID: PMC2859686.
    35. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66. PMID: 19047091.
      View in: PubMed
    36. Basu N, Bhattacharya R, Mukherjee P. Protein-mediated autoreduction of gold salts to gold nanoparticles. Biomed Mater. 2008 Sep; 3(3):034105. PMID: 18689931.
      View in: PubMed
    37. Bhattacharya R, Mukherjee P. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1289-306. PMID: 18501989.
      View in: PubMed
    38. Bhattacharya R, Kwon J, Wang E, Mukherjee P, Mukhopadhyay D. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal. 2008 Mar 31; 3:8. PMID: 18377662; PMCID: PMC2292718.
    39. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15; 68(6):1970-8. PMID: 18339879.
      View in: PubMed
    40. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, Curley SA. Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology. 2008 Jan 30; 6:2. PMID: 18234109; PMCID: PMC2276230.
    41. Patra CR, Bhattacharya R, Patra S, Basu S, Mukherjee P, Mukhopadhyay D. Lanthanide phosphate nanorods as inorganic fluorescent labels in cell biology research. Clin Chem. 2007 Nov; 53(11):2029-31. PMID: 18035595.
      View in: PubMed
    42. Mukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, Kay NE, Mukhopadhyay D. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology. 2007 May 08; 5:4. PMID: 17488514; PMCID: PMC1876244.
    43. Patra CR, Bhattacharya R, Patra S, Basu S, Mukherjee P, Mukhopadhyay D. Inorganic phosphate nanorods are a novel fluorescent label in cell biology. J Nanobiotechnology. 2006 Oct 30; 4:11. PMID: 17074086; PMCID: PMC1636656.
    44. Bhattacharya R, Kang-Decker N, Hughes DA, Mukherjee P, Shah V, McNiven MA, Mukhopadhyay D. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J. 2005 Oct; 19(12):1692-4. PMID: 16049137.
      View in: PubMed
    45. Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P, Mukherjee P, Mukhopadhyay D, Jain MK. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem. 2005 Aug 12; 280(32):28848-51. PMID: 15980434.
      View in: PubMed
    46. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005 May 01; 11(9):3530-4. PMID: 15867256.
      View in: PubMed
    Mukherjee's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _